Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

But the biggest reason Novo isn't overly concerned is because Medicare is not its largest market in the US. Until the start of 2025, only Ozempic and Rybelsus for diabetes were co ...

Donald Trump is executing a shock-and-awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ...

Investigators have recovered the cockpit voice recorder of a medical transport jet that crashed Jan. 31 in Philadelphia, ...